Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of vancomycin, neomycin, and MTT. Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of cell wall precursor units, leading to bactericidal activity against Gram-positive bacteria. Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis and resulting in bactericidal effects primarily against Gram-negative bacteria but also some Gram-positive organisms. The combination of vancomycin and an aminoglycoside like neomycin can act synergistically against certain pathogens[4][3]. "MTT" in this context is ambiguous; it may refer to a chemical moiety or excipient (such as 2-mercapto-1-methylimidazole or another compound), but no standard pharmaceutical use for "vancomycin + neomycin + MTT" as a named product could be identified from available sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vancomycin + neomycin + MTT.